Emodin sensitizes hepatocellular carcinoma cells to the anti-cancer effect of sorafenib through suppression of cholesterol metabolism

Young Seon Kim, Yoon Mi Lee, Taek In Oh, Dong Hoon Shin, Geon Hee Kim, Sang Yeon Kan, Hyeji Kang, Ji Hyung Kim, Byeong Mo Kim, Woo Jong Yim, Ji Hong Lim

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Reduced therapeutic efficacy of sorafenib, a first-generation multikinase inhibitor, is often observed during the treatment of advanced hepatocellular carcinoma (HCC). Emodin is an active component of Chinese herbs, and is effective against leukemia, lung cancer, colon cancer, pancreatic cancer, and HCC; however, the sensitizing effect of emodin on sorafenib-based HCC therapy has not been evaluated. Here, we demonstrate that emodin significantly improved the anti-cancer effect of sorafenib in HCC cells, such as HepG2, Hep3B, Huh7, SK-HEP-1, and PLC/PRF5. Mechanistically, emodin inhibits sterol regulatory element-binding protein-2 (SREBP-2) transcriptional activity, which suppresses cholesterol biosynthesis and oncogenic protein kinase B (AKT) signaling. Additionally, attenuated cholesterol synthesis and oncogenic AKT signaling inactivated signal transducer and activator of transcription 3 (STAT3), an oncogenic transcription factor. Furthermore, emodin synergistically increased cell cycle arrest in the G1 phase and apoptotic cells in the presence of sorafenib. Animal models xenografted with HepG2 or SK-HEP-1 cells also showed that the combination of emodin and sorafenib was sufficient to inhibit tumor growth. Overall, these results suggested that the combination of emodin and sorafenib may offer a potential therapy for patients with advanced HCC.

Original languageEnglish
Article number3127
JournalInternational journal of molecular sciences
Volume19
Issue number10
DOIs
Publication statusPublished - 2018 Oct 12

Fingerprint

Emodin
Cholesterol
cholesterol
metabolism
Metabolism
Hepatocellular Carcinoma
cancer
Cells
retarding
Transcription factors
Biosynthesis
Transcription
Programmable logic controllers
Tumors
Transducers
Neoplasms
Animals
Proteins
Colonic Neoplasms
Sterol Regulatory Element Binding Protein 2

Keywords

  • Cholesterol
  • Combination
  • Emodin
  • Hepatocellular carcinoma
  • Sorafenib

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Emodin sensitizes hepatocellular carcinoma cells to the anti-cancer effect of sorafenib through suppression of cholesterol metabolism. / Kim, Young Seon; Lee, Yoon Mi; Oh, Taek In; Shin, Dong Hoon; Kim, Geon Hee; Kan, Sang Yeon; Kang, Hyeji; Kim, Ji Hyung; Kim, Byeong Mo; Yim, Woo Jong; Lim, Ji Hong.

In: International journal of molecular sciences, Vol. 19, No. 10, 3127, 12.10.2018.

Research output: Contribution to journalArticle

Kim, Young Seon ; Lee, Yoon Mi ; Oh, Taek In ; Shin, Dong Hoon ; Kim, Geon Hee ; Kan, Sang Yeon ; Kang, Hyeji ; Kim, Ji Hyung ; Kim, Byeong Mo ; Yim, Woo Jong ; Lim, Ji Hong. / Emodin sensitizes hepatocellular carcinoma cells to the anti-cancer effect of sorafenib through suppression of cholesterol metabolism. In: International journal of molecular sciences. 2018 ; Vol. 19, No. 10.
@article{016d45d65ac84ab6a558bf2e811490e1,
title = "Emodin sensitizes hepatocellular carcinoma cells to the anti-cancer effect of sorafenib through suppression of cholesterol metabolism",
abstract = "Reduced therapeutic efficacy of sorafenib, a first-generation multikinase inhibitor, is often observed during the treatment of advanced hepatocellular carcinoma (HCC). Emodin is an active component of Chinese herbs, and is effective against leukemia, lung cancer, colon cancer, pancreatic cancer, and HCC; however, the sensitizing effect of emodin on sorafenib-based HCC therapy has not been evaluated. Here, we demonstrate that emodin significantly improved the anti-cancer effect of sorafenib in HCC cells, such as HepG2, Hep3B, Huh7, SK-HEP-1, and PLC/PRF5. Mechanistically, emodin inhibits sterol regulatory element-binding protein-2 (SREBP-2) transcriptional activity, which suppresses cholesterol biosynthesis and oncogenic protein kinase B (AKT) signaling. Additionally, attenuated cholesterol synthesis and oncogenic AKT signaling inactivated signal transducer and activator of transcription 3 (STAT3), an oncogenic transcription factor. Furthermore, emodin synergistically increased cell cycle arrest in the G1 phase and apoptotic cells in the presence of sorafenib. Animal models xenografted with HepG2 or SK-HEP-1 cells also showed that the combination of emodin and sorafenib was sufficient to inhibit tumor growth. Overall, these results suggested that the combination of emodin and sorafenib may offer a potential therapy for patients with advanced HCC.",
keywords = "Cholesterol, Combination, Emodin, Hepatocellular carcinoma, Sorafenib",
author = "Kim, {Young Seon} and Lee, {Yoon Mi} and Oh, {Taek In} and Shin, {Dong Hoon} and Kim, {Geon Hee} and Kan, {Sang Yeon} and Hyeji Kang and Kim, {Ji Hyung} and Kim, {Byeong Mo} and Yim, {Woo Jong} and Lim, {Ji Hong}",
year = "2018",
month = "10",
day = "12",
doi = "10.3390/ijms19103127",
language = "English",
volume = "19",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "10",

}

TY - JOUR

T1 - Emodin sensitizes hepatocellular carcinoma cells to the anti-cancer effect of sorafenib through suppression of cholesterol metabolism

AU - Kim, Young Seon

AU - Lee, Yoon Mi

AU - Oh, Taek In

AU - Shin, Dong Hoon

AU - Kim, Geon Hee

AU - Kan, Sang Yeon

AU - Kang, Hyeji

AU - Kim, Ji Hyung

AU - Kim, Byeong Mo

AU - Yim, Woo Jong

AU - Lim, Ji Hong

PY - 2018/10/12

Y1 - 2018/10/12

N2 - Reduced therapeutic efficacy of sorafenib, a first-generation multikinase inhibitor, is often observed during the treatment of advanced hepatocellular carcinoma (HCC). Emodin is an active component of Chinese herbs, and is effective against leukemia, lung cancer, colon cancer, pancreatic cancer, and HCC; however, the sensitizing effect of emodin on sorafenib-based HCC therapy has not been evaluated. Here, we demonstrate that emodin significantly improved the anti-cancer effect of sorafenib in HCC cells, such as HepG2, Hep3B, Huh7, SK-HEP-1, and PLC/PRF5. Mechanistically, emodin inhibits sterol regulatory element-binding protein-2 (SREBP-2) transcriptional activity, which suppresses cholesterol biosynthesis and oncogenic protein kinase B (AKT) signaling. Additionally, attenuated cholesterol synthesis and oncogenic AKT signaling inactivated signal transducer and activator of transcription 3 (STAT3), an oncogenic transcription factor. Furthermore, emodin synergistically increased cell cycle arrest in the G1 phase and apoptotic cells in the presence of sorafenib. Animal models xenografted with HepG2 or SK-HEP-1 cells also showed that the combination of emodin and sorafenib was sufficient to inhibit tumor growth. Overall, these results suggested that the combination of emodin and sorafenib may offer a potential therapy for patients with advanced HCC.

AB - Reduced therapeutic efficacy of sorafenib, a first-generation multikinase inhibitor, is often observed during the treatment of advanced hepatocellular carcinoma (HCC). Emodin is an active component of Chinese herbs, and is effective against leukemia, lung cancer, colon cancer, pancreatic cancer, and HCC; however, the sensitizing effect of emodin on sorafenib-based HCC therapy has not been evaluated. Here, we demonstrate that emodin significantly improved the anti-cancer effect of sorafenib in HCC cells, such as HepG2, Hep3B, Huh7, SK-HEP-1, and PLC/PRF5. Mechanistically, emodin inhibits sterol regulatory element-binding protein-2 (SREBP-2) transcriptional activity, which suppresses cholesterol biosynthesis and oncogenic protein kinase B (AKT) signaling. Additionally, attenuated cholesterol synthesis and oncogenic AKT signaling inactivated signal transducer and activator of transcription 3 (STAT3), an oncogenic transcription factor. Furthermore, emodin synergistically increased cell cycle arrest in the G1 phase and apoptotic cells in the presence of sorafenib. Animal models xenografted with HepG2 or SK-HEP-1 cells also showed that the combination of emodin and sorafenib was sufficient to inhibit tumor growth. Overall, these results suggested that the combination of emodin and sorafenib may offer a potential therapy for patients with advanced HCC.

KW - Cholesterol

KW - Combination

KW - Emodin

KW - Hepatocellular carcinoma

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=85054891539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054891539&partnerID=8YFLogxK

U2 - 10.3390/ijms19103127

DO - 10.3390/ijms19103127

M3 - Article

C2 - 30321984

AN - SCOPUS:85054891539

VL - 19

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 10

M1 - 3127

ER -